Please wait

Exhibit 21

List of Subsidiaries

Entity name			Place of Incorporation			Ownership % as of December 31, 2025
BB Square Capital Investors I, LP			Delaware			100.0%
BB Square Capital, LLC			Delaware			100.0%
BB Square Holdings, LLC			Delaware			100.0%
BB Square Investors GP I, LLC			Delaware			100.0%
BB Square LP Investment, LLC			Delaware			100.0%
BridgeBio Chemistry, Inc.			Delaware			100.0%
BridgeBio Gene Therapy LLC			Delaware			100.0%
BridgeBio Gene Therapy Research, Inc.			Delaware			100.0%
BridgeBio Pharma LLC			Delaware			100.0%
BridgeBio Services Inc.			Delaware			100.0%
Calcilytix Therapeutics, Inc.			Delaware			100.0%
Cyan Therapeutics, Inc.			Delaware			100.0%
DTD Therapeutics, Inc.			Delaware			100.0%
Eidos Therapeutics, Inc.			Delaware			100.0%
CoA Therapeutics, Inc.			Delaware			99.9%
Origin Biosciences, Inc.			Delaware			99.9%
Adrenas Therapeutics, Inc.			Delaware			99.3%
QED Therapeutics, Inc.			Delaware			99.3%
Sub22, Inc.			Delaware			98.5%
Ferro Therapeutics, Inc.			Delaware			98.2%
Eulamin Therapeutics, Inc.			Delaware			98.0%
Cantero Therapeutics, Inc.			Delaware			96.5%
Venthera, Inc.			Delaware			96.2%
G Protein Therapeutics, Inc.			Delaware			94.6%
Molecular Skin Therapeutics, Inc.			Delaware			91.5%
Phoenix Tissue Repair, Inc.			Delaware			86.6%
Navire Pharma, Inc.			Delaware			81.5%
ML Bio Solutions, Inc.			Delaware			89.5%
Sen Therapeutics, Inc.			Delaware			89.8%
Audition Therapeutics, Inc.			Delaware			37.5%
BridgeBio Pharma Canada, ULC			Canada			100.0%
BridgeBio Pharma Cayman			Cayman Islands			100.0%
BridgeBio France SAS			France			100.0%
BridgeBio Germany GmbH			Germany			100.0%
BridgeBio Pharma (HK) Limited			Hong Kong			100.0%
BridgeBio Europe B.V.			Netherlands			100.0%
BridgeBio International GmbH			Switzerland			100.0%
BridgeBio UK Limited			United Kingdom			100.0%
Evanesco Therapeutics, Inc.			Delaware			100.0%
BridgeBio Pharma Europe B.V.			Netherlands			100.0%